BeOne Medicines AG (6160.HK) stock analysis

In our weekly check, BeOne Medicines AG is graded B (A to F). Of 23 checks on debt, profit, cash flow and trend: 18 pass, warnings: 4, red flags: 1.

About BeOne Medicines AG

BeOne Medicines AG is a Healthcare company (Biotechnology) based in Switzerland, listed on HKSE as 6160.HK.

What our checks show for 6160.HK

Red flags

• The stock has fallen as much as 73% from a peak. Would you have held through that?

Warning signs

• Earnings per share fell 32.7% a year over the last 3 years.
• The price swings a lot: 38% annual volatility. Expect large ups and downs.
• The stock is still below its previous peak.
• Pay in shares equals 40% of free cash flow: it dilutes shareholders.

Strengths

• Debt is low: 0.22x equity.
• Operating profit covers interest 9.9 times over.
• The net margin rose by 135 points over 5 years, to 10.7%.
• The gross margin is 87.8% and has risen by 126 points: pricing power is holding.
• Operating cash flow is 2.27x net profit: the profit arrives as real cash.
• Analysts expect earnings per share to grow about 39.7% a year over the next years.

Next earnings report: 2026-11-05

Similar companies

RVMD · ALNY · ARGX · GMAB · ROIV · UTHR

Questions

What grade does BeOne Medicines AG (6160.HK) have?

In our weekly check, BeOne Medicines AG is graded B (A to F). Of 23 checks on debt, profit, cash flow and trend: 18 pass, warnings: 4, red flags: 1. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of 6160.HK stock?

This week's biggest flags for BeOne Medicines AG: Deep past fall, Weak EPS growth, Very volatile. In total 5 of 23 checks show a warning or a red flag.

What does BeOne Medicines AG do?

BeOne Medicines AG is a Healthcare company (Biotechnology) based in Switzerland, listed on HKSE as 6160.HK.

When does BeOne Medicines AG report earnings next?

The next earnings report is expected on 2026-11-05. We re-run the checks every week, so the grade can change after it.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-10-24

Open the full analysis